SCHEMBL2969092

SCHEMBL2969092

Nc1nc(C[C@@H]2CCCO2)c2c(-c3ccccc3)c(-c3ccccc3)oc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 17/20 0.53
LCK P06239 7/20 0.53
KDR P35968 1/20 0.53
JAK3 P52333 1/20 0.53
ABL1 P00519 1/20 0.53
LYN P07948 1/20 0.53
BTK Q06187 1/20 0.53
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2974800 0.70 TNK2 (1.00) TNK2LCKKDRJAK3ABL1
SCHEMBL2967661 0.70 TNK2 (1.00) TNK2LCKKDRJAK3ABL1
SCHEMBL2965872 0.70 TNK2 (1.00) TNK2LCKKDRJAK3ABL1
SCHEMBL3562484 0.70 TNK2 (1.00) TNK2LCKKDRJAK3ABL1
SCHEMBL2975441 0.69 TNK2 (0.89) TNK2LCKKDRJAK3ABL1
SCHEMBL13461961 0.67 TNK2 (0.73) TNK2LCKKDRJAK3ABL1
SCHEMBL3564171 0.67 TNK2 (0.73) TNK2LCKKDRJAK3ABL1
SCHEMBL6364218 0.67 CYP1A2 (0.33) TNK2ADORA2AADORA2BMEN1CYP1A2
SCHEMBL2963954 0.66 TNK2 (0.82) TNK2LCKKDRJAK3ABL1
SCHEMBL2975018 0.66 TNK2 (0.90) TNK2LCKKDRJAK3ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US claimed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP claimed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US claimed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO claimed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP disclosed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US disclosed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 TNK2 1075/4885LCK 18/4885KDR 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.